Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 18/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 10/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 4/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 4/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 1.00 |
| ▸ | PIP5K1C | O60331 | 1/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
| ▸ | PIK3R4 | Q99570 | 1/20 | 1.00 |
| ▸ | PIP5K1A | Q99755 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.47 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.47 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9957245 | 1.00 | PIK3C3 (1.00) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957247 | 0.90 | PIK3C3 (0.83) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957623 | 0.90 | PIK3C3 (1.00) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957785 | 0.86 | PIK3C3 (0.83) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957195 | 0.84 | PIK3C3 (0.79) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9956230 | 0.84 | PIK3C3 (0.79) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957794 | 0.83 | PIK3C3 (0.77) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9956997 | 0.82 | PIK3C3 (1.00) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957109 | 0.80 | PIK3C3 (0.70) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957099 | 0.79 | PIK3C3 (0.68) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12458630-B2 | Combination therapy for cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-04 | — | — | US | claimed |
| US-20240294876-A1 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIV SOUTHERN CALIFORNIA (US) | 2024-09-05 | — | — | US | claimed |
| EP-4341386-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | University of Southern California (US) | 2024-03-27 | — | — | EP | claimed |
| CN-117751182-A | Method for amplifying human granulocyte-macrophage progenitor cells and application thereof | 南加利福尼亚大学 | 2024-03-22 | — | — | CN | claimed |
| US-20240043390-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-08 | — | — | US | claimed |
| CN-117159715-A | New use of inhibitor and inhibitor screening model | 中国农业大学 | 2023-12-05 | — | — | CN | claimed |
| US-20230190736-A1 | SMALL MOLECULE THERAPEUTICS FOR THE TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-22 | — | — | US | claimed |
| US-20230068698-A1 | COMBINATION THERAPY FOR CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-02 | — | — | US | claimed |
| EP-4114946-A1 | METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPY | Regeneron Pharmaceuticals, Inc. (US) | 2023-01-11 | — | — | EP | claimed |
| CN-115485385-A | Methods and compositions for sensitizing tumor cells to immunotherapy | 瑞泽恩制药公司 | 2022-12-16 | — | — | CN | claimed |
| WO-2022245977-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-11-24 | — | — | WO | claimed |
| US-20220193056-A1 | COMPOSITIONS AND METHODS OF TREATING PIK3CA HELICAL DOMAIN MUTANT CANCERS | CASE WESTERN RESERVE UNIVERSITY | 2022-06-23 | — | — | US | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743080-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20220072139-A1 | STEREOCOMPLEXES FOR THE DELIVERY OF ANTI-CANCER AGENTS | TIEN DER YANG (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072139-A1 | STEREOCOMPLEXES FOR THE DELIVERY OF ANTI-CANCER AGENTS | TOP2A, TSG101, TOP1 | PIK3C3 4721/4885PIK3CD 991/4885PIK3CA 1117/4885 |
| US-20240043390-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | PIK3C3 621/4885PIK3CD 563/4885PIK3CA 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.